Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)

The EXIT-CJS (N  = 1005) multisite open-label randomized controlled trial will compare retention and effectiveness of extended-release buprenorphine (XR-B) vs. extended-release naltrexone (XR-NTX) to treat opioid use disorder (OUD) among criminal justice system (CJS)-involved adults in six U.S. locales (New Jer sey, New York City, Delaware, Oregon, Connecticut, and New Hampshire). With a pragmatic, noninferiority design, this study hypothesizes that XR-B (n = 335) will be noninferior to XR-NTX (n = 335) in retention-in-study-medication treatment (the primary outcome), self-reported opioid use, opio id-positive urine samples, opioid overdose events, and CJS recidivism.

Source: Journal of Substance Abuse Treatment - April 8, 2021 Category: Addiction Authors: Elizabeth Needham Waddell, Sandra A. Springer, Lisa A. Marsch, David Farabee, Robert P. Schwartz, Amesika Nyaku, Rusty Reeves, Keith Goldfeld, Ryan D. McDonald, Mia Malone, Anna Cheng, Elizabeth C. Saunders, Laura Monica, Jan Gryczynski, Kathleen Bell, Ka Source Type: research